UniProtKB/Swiss-Prot Q96NR8: Variant p.Ala47Thr

Retinol dehydrogenase 12
Gene: RDH12
Feedback?

Variant information Variant position:

47 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Alanine (A) to Threonine (T) at position 47 (A47T, p.Ala47Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from small size and hydrophobic (A) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In retinal dystrophy; exhibits a profound loss of catalytic activity. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs761231974 [ dbSNP | Ensembl ]

Sequence information Variant position:

47 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

316 The length of the canonical sequence.
Location on the sequence:

AGGVCRTNVQLPGKVVVITG A NTGIGKETARELASRGARVY The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         AGGVCRTNVQLPGKVVVITGANTGIGKETARELASRGARVY

Mouse                         AGGVCTTNVQIPGKVVVITGANTGIGKETARELARRGARVY

Bovine                        AGGVCRTDVQLFGKVVVITGANTGIGKETARELARRGARVY

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 316	Retinol dehydrogenase 12
Binding site	46 – 52

Literature citations
Retinal degeneration associated with RDH12 mutations results from decreased 11-cis retinal synthesis due to disruption of the visual cycle.
Thompson D.A.; Janecke A.R.; Lange J.; Feathers K.L.; Hubner C.A.; McHenry C.L.; Stockton D.W.; Rammesmayer G.; Lupski J.R.; Antinolo G.; Ayuso C.; Baiget M.; Gouras P.; Heckenlively J.R.; den Hollander A.; Jacobson S.G.; Lewis R.A.; Sieving P.A.; Wissinger B.; Yzer S.; Zrenner E.; Utermann G.; Gal A.;
Hum. Mol. Genet. 14:3865-3875(2005)
Cited for: VARIANTS RETINAL DYSTROPHY THR-47; MET-55; ILE-99; LYS-125; GLU-145; ASP-151; ILE-155; CYS-193; ASP-206; VAL-206; LEU-230; HIS-234; TRP-239; PRO-274 AND TYR-285; VARIANTS GLN-65; ASN-101; GLN-161 AND CYS-193; CHARACTERIZATION OF VARIANTS RETINAL DYSTROPHY THR-47; MET-55; ILE-99; LYS-125; GLU-145; ASP-151; ILE-155; CYS-193; ASP-206; VAL-206; LEU-230; HIS-234; TRP-239; PRO-274 AND TYR-285; CHARACTERIZATION OF VARIANT GLN-161;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.